Ben Ho Park
YOU?
Author Swipe
View article: Proteomic Analysis of PTEN-Deficient Cells Reveals Src-Mediated Upregulation of EphA2 and Therapeutic Potential of Dual Inhibition
Proteomic Analysis of PTEN-Deficient Cells Reveals Src-Mediated Upregulation of EphA2 and Therapeutic Potential of Dual Inhibition Open
Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) is frequently observed in various cancers and promotes tumorigenesis by activating the PI3K-AKT pathway. However, the effectiveness of therapies targeting this pathway is l…
View article: Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors Open
Gene fusions are a class of important oncogenic drivers, with many matched FDA-approved targeted therapies across multiple solid tumors. However, the prevalence of fusions varies considerably by cancer type and assay. Fusion detection is t…
View article: Distinct and convergent effects of <i>SF3B1</i> mutations in human breast cancer
Distinct and convergent effects of <i>SF3B1</i> mutations in human breast cancer Open
Tumor genomic profiling has uncovered many cancer drivers whose implications in terms of tumor biology and therapeutic actionability remain understudied. Hotspot mutations in SF3B1 induce widespread transcriptomic alterations and occur acr…
View article: Clonal Hematopoiesis of Indeterminate Potential After Radiation Therapy
Clonal Hematopoiesis of Indeterminate Potential After Radiation Therapy Open
In this cohort study, prior RT was associated with an increased risk of clonal hematopoiesis, particularly among patients receiving higher biologically equivalent radiation doses, stereotactic techniques, or treatment to the spine.
View article: Chatbot assistance in precision oncology treatment decision-making
Chatbot assistance in precision oncology treatment decision-making Open
Artificial intelligence chatbots have shown promise in medical settings, but their ability to interpret complex molecular data is not clear. Here, we assessed 50 different patient scenarios with clinical and molecular data and found that c…
View article: Supplementary Data1 from Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer
Supplementary Data1 from Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer Open
Supplemental tables and figures
View article: Data from Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer
Data from Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer Open
Purpose:We report herein a phase Ib trial to determine the safety, tolerability, and antitumor activity of erdafitinib, a pan-FGFR tyrosine kinase inhibitor, with fulvestrant and palbociclib in patients with hormone receptor–positive/HER2-…
View article: Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer
Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer Open
Cancer-associated fibroblasts (CAFs) are part of the tumor microenvironment (TME) that enable cancer cells to establish metastases, but the mechanisms of these interactions are not fully known. Herein, we identified a paracrine mechanism i…
View article: Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer
Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer Open
Purpose: We report herein a phase Ib trial to determine the safety, tolerability, and antitumor activity of erdafitinib, a pan-FGFR tyrosine kinase inhibitor, with fulvestrant and palbociclib in patients with hormone receptor–positive/HER2…
View article: Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the <i>All of Us Research Program</i> Cohort
Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the <i>All of Us Research Program</i> Cohort Open
Background Hormone therapy (HT) has greatly improved overall survival for prostate cancer patients, but may also influence cardiovascular health in an already high‐risk population. Methods This retrospective cohort study examined participa…
View article: Proteomic Analysis of PTEN-Deficient Cells Reveals Src-Mediated Upregulation of EphA2 and Therapeutic Potential of Dual Inhibition
Proteomic Analysis of PTEN-Deficient Cells Reveals Src-Mediated Upregulation of EphA2 and Therapeutic Potential of Dual Inhibition Open
Loss of the tumor suppressor PTEN is frequently observed in various cancers and promotes tumorigenesis by activating the PI3K-AKT pathway. However, the effectiveness of therapies targeting this pathway is limited by complex signaling cross…
View article: Prevalence and Associated Factors for Depression Among Patients With Sarcoma
Prevalence and Associated Factors for Depression Among Patients With Sarcoma Open
PURPOSE Prevalence and risk factors for depression among patients with sarcoma and survivors of sarcoma are not well characterized. METHODS A sarcoma survivorship cohort was constructed from patients diagnosed between April 2022 and Septem…
View article: Strengthening Asian/Asian American, Native Hawaiian, and Pacific Islander Leadership in Cancer Research
Strengthening Asian/Asian American, Native Hawaiian, and Pacific Islander Leadership in Cancer Research Open
Summary: Individuals in the United States from Asian and Asian American, Native Hawaiian, and Pacific Islander (AANHPI) backgrounds face a distinct set of cancer-related disparities. In this study, in conjunction with the American Associat…
View article: Association Between Major Adverse Cardiac Events and Hormone Therapy Usage in Prostate Cancer Patients of a Diverse Cohort
Association Between Major Adverse Cardiac Events and Hormone Therapy Usage in Prostate Cancer Patients of a Diverse Cohort Open
Importance Hormone therapy (HT) has led to improved overall survival for prostate cancer patients, but may also increase cardiovascular risk. Objective To compare time-to-event for major adverse cardiovascular events (MACE) between those w…
View article: Risk of Clonal Hematopoiesis of Indeterminate Potential after Cancer Radiation Therapy
Risk of Clonal Hematopoiesis of Indeterminate Potential after Cancer Radiation Therapy Open
Clonal hematopoiesis of indeterminate potential (CHIP) is a condition associated with aging and increased risk of hematologic malignancies and chronic diseases. While radiation therapy (RT) has been implicated as a risk factor for CHIP, th…
View article: Patient Navigation Improved Breast Cancer Outcomes Among Women in the Public System in Rio de Janeiro, Brazil
Patient Navigation Improved Breast Cancer Outcomes Among Women in the Public System in Rio de Janeiro, Brazil Open
Purpose: To evaluate whether a Breast Cancer (BC) Patient Navigation Program (PNP) contributes to increasing compliance with the "60-Day Law, " which mandates that cancer treatment must start within 60 days of a definitive diagnosis.Conseq…
View article: An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release
An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release Open
Abtract Clinical circulating cell-free DNA (cfDNA) testing is now routine, however test accuracy remains limited. By understanding the life-cycle of cfDNA, we might identify opportunities to increase test performance. Here, we profile cfDN…
View article: Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data
Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data Open
PURPOSE Although immune checkpoint inhibitors (ICIs) have improved outcomes in certain patients with cancer, they can also cause life-threatening immunotoxicities. Predicting immunotoxicity risks alongside response could provide a personal…
View article: Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131
Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131 Open
Background Patient‐reported outcomes (PROs) are a better tool for evaluating the experiences of patients who have symptomatic, treatment‐associated adverse events (AEs) compared with clinician‐rated AEs. The authors present PROs assessing …
View article: Genomic dissection and mutation-specific target discovery for breast cancer<i>PIK3CA</i>hotspot mutations
Genomic dissection and mutation-specific target discovery for breast cancer<i>PIK3CA</i>hotspot mutations Open
Background Recent advancements in high-throughput genomics and targeted therapies have provided tremendous potential to identify and therapeutically target distinct mutations associated with cancers. However, to date the majority of target…
View article: Volumetric sonographic depiction of the fallopian tube lumen for the early detection of tubal abnormalities: A work in progress
Volumetric sonographic depiction of the fallopian tube lumen for the early detection of tubal abnormalities: A work in progress Open
Objectives: The fallopian tube (FT) has emerged as an important imaging target in the detection of early ovarian cancer, which has remained an evasive challenge in the field of medicine. Recent understanding of ovarian cancer has identifie…
View article: 1492 Clonal hematopoiesis of indeterminate potential alters solid tumor microenvironment and outcomes in triple negative breast cancer
1492 Clonal hematopoiesis of indeterminate potential alters solid tumor microenvironment and outcomes in triple negative breast cancer Open
Background Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by blood cells with somatic mutations in leukemia-associated genes in patients without hematologic malignancies. The incidence of CHIP increases with age, a…
View article: OR16-06 A Novel Pathway Controlling Anticancer Drug Induced Immunogenic Necrosis In ERα Positive Cancer Cells
OR16-06 A Novel Pathway Controlling Anticancer Drug Induced Immunogenic Necrosis In ERα Positive Cancer Cells Open
Disclosure: J. Zhu: None. S. Ghosh: None. D. Duraki: None. M. Boudreau: Other; Self; Patent on ErSO. M. Jabeen: None. C. Mao: None. B. Park: None. G. Cheng: None. E.R. Nelson: None. P.J. Hergenrother: Advisory Board Member; Self; System On…
View article: Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis
Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis Open
Supplementary Movie 4
View article: Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis
Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis Open
Supplementary Movie 2
View article: Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis
Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis Open
Supplementary Movie 1
View article: Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis
Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis Open
Supplementary Movie 2